Will DigitalOcean Stock Bounce Back?
DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…
Sell
45
PFE Quote, Financials, Valuation and Earnings
Last price:
$23.34
Seasonality move
:
1.95%
Day range:
$22.88 - $23.39
52-week range:
$20.92 - $31.54
Dividend yield:
7.29%
P/E ratio:
16.90x
P/S ratio:
2.13x
P/B ratio:
1.47x
Volume:
31.7M
Avg. volume:
48.7M
1-year change:
-18.72%
Market cap:
$132.6B
Revenue:
$63.6B
EPS (TTM):
$1.38
Analysts' Opinion
-
Consensus RatingPfizer has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 15 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $29.50, Pfizer has an estimated upside of 26.5% from its current price of $23.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 1.37% downside risk from its current price of $23.32.
Fair Value
-
According to the consensus of 23 analysts, Pfizer has 26.5% upside to fair value with a price target of $29.50 per share.
PFE vs. S&P 500
-
Over the past 5 trading days, Pfizer has overperformed the S&P 500 by 4.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pfizer does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pfizer revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pfizer reported revenues of $13.7B.
Earnings Growth
-
Pfizer earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pfizer reported earnings per share of $0.52.
Enterprise value:
176.9B
EV / Invested capital:
1.16x
Price / LTM sales:
2.13x
EV / EBIT:
17.10x
EV / Revenue:
2.83x
PEG ratio (5yr expected):
0.06x
EV / Free cash flow:
15.76x
Price / Operating cash flow:
11.85x
Enterprise value / EBITDA:
10.26x
Gross Profit (TTM):
$45.1B
Return On Assets:
3.66%
Net Income Margin (TTM):
12.62%
Return On Equity:
8.72%
Return On Invested Capital:
5.05%
Operating Margin:
32.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $94B | $55.9B | $62.5B | $14.9B | $13.7B | |
| Gross Profit | $64.8B | $32.5B | $45.1B | $11.5B | $10.9B | |
| Operating Income | $34.7B | $2B | $15.2B | $4.2B | $4.4B | |
| EBITDA | $38.5B | $7.4B | $17.2B | $5.9B | $5.1B | |
| Diluted EPS | $5.08 | -$0.06 | $1.38 | $0.55 | $0.52 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.5B | $54.4B | $50.1B | $42.4B | $45.9B | |
| Total Assets | $158.8B | $183.8B | $195.6B | $221.1B | $208B | |
| Current Liabilities | $26.7B | $39.3B | $36.6B | $40.5B | $36.5B | |
| Total Liabilities | $90B | $101.2B | $94.4B | $128.5B | $117.4B | |
| Total Equity | $68.9B | $82.7B | $101.2B | $92.6B | $90.6B | |
| Total Debt | $38.2B | $35.1B | $34.9B | $68.7B | $61.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $23.9B | $8.6B | $14B | $1.1B | $2.3B | |
| Cash From Investing | -$13B | -$33.9B | $4.2B | $1.7B | $3.3B | |
| Cash From Financing | -$11B | $23.9B | -$17.4B | -$4.9B | -$5.2B | |
| Free Cash Flow | $20.2B | $5.1B | $11.2B | $386M | $1.8B | |
PFE
Sector
Market Cap
$132.6B
$34.8M
Price % of 52-Week High
73.94%
44.2%
Dividend Yield
7.29%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-18.72%
-41.1%
Beta (5-Year)
0.588
0.659
Dividend yield:
7.29%
Annualized payout:
$1.68
Payout ratio:
121.49%
Growth streak:
14 years
Technicals
8-day SMA
Buy
Level
$22.92
200-day SMA
Sell
Level
$26.44
Bollinger Bands (100)
Sell
Level
23.26 - 26.64
Chaikin Money Flow
Sell
Level
-1.2B
20-day SMA
Buy
Level
$23.18
Relative Strength Index (RSI14)
Buy
Level
51.53
ADX Line
Buy
Level
14.97
Williams %R
Neutral
Level
-29.6875
50-day SMA
Sell
Level
$23.62
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Sell
Level
-4.2B
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9995)
Sell
CA Score
(Annual)
Level (-0.5703)
Buy
Beneish M-Score
(Annual)
Level (-2.676)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-1.6803)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Stock Forecast FAQ
In the current month, PFE has received 7 Buy ratings 15 Hold ratings, and 1 Sell ratings. The PFE average analyst price target in the past 3 months is $29.50.
-
Where Will Pfizer Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pfizer share price will rise to $29.50 per share over the next 12 months.
-
What Do Analysts Say About Pfizer?
Analysts are divided on their view about Pfizer share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pfizer is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Pfizer's Price Target?
The price target for Pfizer over the next 1-year time period is forecast to be $29.50 according to 23 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is PFE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pfizer is a Hold. 15 of 23 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PFE?
You can purchase shares of Pfizer via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pfizer shares.
-
What Is The Pfizer Share Price Today?
Pfizer was last trading at $23.34 per share. This represents the most recent stock quote for Pfizer. Yesterday, Pfizer closed at $23.32 per share.
-
How To Buy Pfizer Stock Online?
In order to purchase Pfizer stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Cognizant Stock Be In 5 Years?
Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…
NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
